The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Gilead Sciences Announces Third Quarter 2012 Financial Results

<p class='bwalignc'> <i><b>- Product Sales of $2.36 Billion, Up 14 Percent over Third Quarter of 2011 -</b></i> </p> <p class='bwalignc'> <i><b>- Antiviral Product Sales of $2.04 Billion, Up 13 Percent over Third Quarter of 2011 -</b></i> </p>

Tuesday, October 23, 2012

Gilead Sciences Announces Third Quarter 2012 Financial Results16:01 EDT Tuesday, October 23, 2012 FOSTER CITY, Calif. (Business Wire) -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the quarter ended September 30, 2012. Total revenues for the third quarter of 2012 increased 14 percent to $2.43 billion, from $2.12 billion for the third quarter of 2011. Net income for the third quarter of 2012 was $675.5 million, or $0.85 per diluted share compared to $741.1 million, or $0.95 per diluted share for the third quarter of 2011. Non-GAAP net income for the third quarter of 2012, which excludes acquisition-related, restructuring and stock-based compensation expenses, was $788.9 million, or $1.00 per diluted share compared to $795.2 million, or $1.02 per diluted share for the third quarter of 2011. Product Sales Product sales increased 14 percent to $2.36 billion for the third quarter of 2012 compared to $2.07 billion for the third quarter of 2011. This increase in product sales was due primarily to Gilead's antiviral franchise, resulting from increased sales of Complera®/Eviplera® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg), Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) and Truvada® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) as well as the launch of StribildTM (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). Antiviral Franchise Antiviral product sales increased 13 percent to $2.04 billion for the third quarter of 2012, up from $1.79 billion for the third quarter of 2011, reflecting sales growth of 19 percent in the U.S. and 5 percent in Europe. AtriplaSales of Atripla increased 9 percent to $865.4 million for the third quarter of 2012, up from $794.7 million for the third quarter of 2011, reflecting sales growth of 8 percent in the U.S. and 6 percent in Europe. TruvadaSales of Truvada increased 8 percent to $804.2 million for the third quarter of 2012, up from $744.7 million for the third quarter of 2011, reflecting sales growth of 16 percent in the U.S. and 3 percent in Europe. VireadSales of Viread® (tenofovir disoproxil fumarate) increased 11 percent to $214.9 million for the third quarter of 2012, up from $192.9 million for the third quarter of 2011, reflecting sales growth of 13 percent in the U.S. partially offset by a decrease of 1 percent in Europe. Complera/EvipleraSales of Complera/Eviplera grew more than fivefold to $99.3 million for the third quarter of 2012 compared to $19.0 million for the third quarter of 2011. Complera was approved in the U.S. in August 2011, and Eviplera was approved in the European Union in November 2011. StribildSales of our newest product, Stribild, which was launched in the U.S. in August 2012, were $17.5 million for the third quarter of 2012. Cardiopulmonary Franchise Cardiopulmonary product sales increased 24 percent to $200.1 million for the third quarter of 2012, up from $160.9 million for the third quarter of 2011. LetairisSales of Letairis® (ambrisentan) increased 33 percent to $105.1 million for the third quarter of 2012, up from $79.0 million for the third quarter of 2011. RanexaSales of Ranexa® (ranolazine) increased 16 percent to $95.1 million for the third quarter of 2012, up from $82.0 million for the third quarter of 2011. Other Products Sales of other products were $122.0 million for the third quarter of 2012 compared to $110.3 million for the third quarter of 2011 and included AmBisome® (amphotericin B) liposome for injection and Cayston® (aztreonam for inhalation solution). Royalty, Contract and Other Revenues Royalty, contract and other revenues were $68.6 million for the third quarter of 2012, up 23 percent from $55.8 million for the third quarter of 2011, due to an increase in royalty revenues, which included higher royalties from GlaxoSmithKline Inc. for Volibris® and Japan Tobacco for Truvada. Research and Development Expenses Research and development (R&D) expenses for the third quarter of 2012 were $465.8 million compared to $290.1 million for the third quarter of 2011. Non-GAAP R&D expenses for the third quarter of 2012, which exclude acquisition-related, restructuring and stock-based compensation expenses, were $383.6 million compared to $269.3 million for the third quarter of 2011 due primarily to the continued advancement of Gilead's product pipeline, particularly in liver disease and oncology. Selling, General and Administrative Expenses Selling, general and administrative (SG&A) expenses for the third quarter of 2012 were $319.6 million compared to $295.9 million for the third quarter of 2011. Non-GAAP SG&A expenses for the third quarter of 2012, which exclude acquisition-related, restructuring and stock-based compensation expenses, were $287.2 million compared to $265.1 million for the third quarter of 2011 due primarily to increased expenses to support the ongoing growth of Gilead's business and an increase in the U.S. pharmaceutical excise tax, partially offset by lower bad debt expense. Interest Expense and Other Income (Expense), Net Interest expense for the third quarter of 2012 was $89.3 million compared to $43.1 million for the third quarter of 2011. The increase was due primarily to the additional debt issued in connection with the acquisition of Pharmasset Inc. (Pharmasset). Other income (expense), net for the third quarter of 2012 was a net expense of $3.5 million compared to net income of $14.4 million in the third quarter of 2011. The change was due primarily to decreased interest income resulting from lower cash, cash equivalents and marketable securities and lower yields. Net Foreign Currency Exchange Impact The net foreign currency exchange impact on third quarter 2012 product sales and pre-tax earnings was an unfavorable $20.5 million and $7.2 million, respectively, compared to the third quarter of 2011. Cash, Cash Equivalents and Marketable Securities As of September 30, 2012, Gilead had $2.65 billion of cash, cash equivalents and marketable securities compared to $9.96 billion as of December 31, 2011. The decrease was due to the acquisition of Pharmasset in the first quarter of 2012. Gilead generated $2.49 billion of operating cash flow during the first nine months of 2012 including $745.4 million generated in the third quarter of 2012. The operating cash flow for the first nine months of 2012 includes the collection of $460 million of accounts receivable in Spain. Corporate Highlights In August, Gilead together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, announced a collaboration agreement to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries - including single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines. Product and Pipeline UpdateAntiviral Franchise In July, Gilead announced: The U.S. Food and Drug Administration (FDA) approved once-daily oral Truvada, in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk for acquiring HIV. Truvada is the first drug to be approved for HIV prevention in uninfected adults, a strategy called pre-exposure prophylaxis (PrEP). 24-week data from a Phase 3 clinical trial, SPIRIT(Switching boosted PI to Rilpivirine In Combination with Truvada as a Single Tablet Regimen), which evaluated virologically suppressed treatment-experienced HIV patients switching from a multi-pill regimen containing a ritonavir-boosted protease inhibitor to the once-daily single tablet regimen Complera. The study met its 24-week primary endpoint, which found that switching to Complera was non-inferior to remaining on a ritonavir-boosted protease inhibitor regimen. The findings were presented in an oral session at the 19th International AIDS Conference in Washington, D.C. Two-year Phase 3 clinical trial results showing that the integrase inhibitor elvitegravir dosed once daily is non-inferior to raltegravir dosed twice daily among treatment-experienced HIV patients. The findings were presented in an oral session at the 19th International AIDS Conference in Washington, D.C. Full clinical trial results from a pivotal Phase 3 study evaluating cobicistat, a pharmacoenhancing or “boosting” agent for HIV therapy, compared to ritonavir, currently the only approved agent used to boost certain antiretroviral treatment regimens. The study found that an HIV regimen containing a cobicistat-boosted protease inhibitor was non-inferior to a regimen containing a ritonavir-boosted protease inhibitor at 48 weeks of therapy. The findings were presented in an oral session at the 19th International AIDS Conference in Washington, D.C. In August, the FDA approved Stribild, a complete once-daily single tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults. Stribild, previously referred to as “Quad” prior to FDA approval, combines four compounds in one daily tablet: elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. Conference Call At 4:15 p.m. Eastern Time today, Gilead's management will host a conference call and a simultaneous webcast to discuss results from its third quarter 2012, provide an update on Gilead's full year 2012 guidance, as well as provide a general business update, including an update on pipeline advancements. To access the webcast live via the internet, please connect to the company's website at www.gilead.com 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call 1-800-659-1966 (U.S.) or 1-617-614-2711 (international) and dial the participant passcode 31853534 to access the call. A replay of the webcast will be archived on the company's website for one year, and a phone replay will be available approximately two hours following the call through October 26, 2012. To access the phone replay, please call 1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the participant passcode 84574172. About Gilead Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific. Non-GAAP Financial Information Gilead has presented certain financial information in accordance with U.S. GAAP (GAAP) and also on a non-GAAP basis for the third quarter of 2012 and 2011. Management believes this non-GAAP information is useful for investors, taken in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under U.S. GAAP. A reconciliation between GAAP and non-GAAP financial information is provided in the table on page 7. Forward-looking Statements Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2012 financial results; Gilead's ability to sustain growth in revenues for its antiviral, cardiopulmonary and respiratory franchises; the availability of funding for state AIDS Drug Assistance Programs (ADAPs) and their ability to purchase at levels to support the number of patients that rely on ADAPs; continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; the possibility of unfavorable results from additional arms of the ATOMIC, ELECTRON and QUANTUM studies and subsequent clinical trials involving GS-7977 and ribavirin and GS-7977 plus pegylated interferon and ribavirin; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated, including GS-7977 for the treatment of hepatitis C (HCV); Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including cobicistat or elvitegravir; Gilead's ability to successfully commercialize its products, including Complera/Eviplera and Stribild; Gilead's ability to successfully develop its respiratory, cardiopulmonary and oncology franchises; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS-7977; the potential for additional austerity measures in European countries that may increase the amount of discount required on Gilead's products; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; Gilead's ability to advance Pharmasset's product pipeline or develop an all-oral antiviral regimen for HCV; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market-specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates. You are urged to consider statements that include the words may, will, would, could, should, might, believes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal, or the negative of those words or other comparable words to be uncertain and forward-looking. Gilead directs readers to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and other subsequent disclosure documents filed with the Securities and Exchange Commission and press releases. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. We own or have rights to various trademarks, copyrights and trade names used in our business, including the following: GILEAD®, GILEAD SCIENCES®, TRUVADA®, VIREAD®, HEPSERA®, AMBISOME®, EMTRIVA®, COMPLERA®, EVIPLERA®, STRIBILDTM, VISTIDE®, LETAIRIS®, VOLIBRIS®, RANEXA®, CAYSTON® and RAPISCAN®. ATRIPLA® is a registered trademark belonging to Bristol-Myers Squibb & Gilead Sciences, LLC.LEXISCAN® is a registered trademark belonging to Astellas U.S. LLC.MACUGEN® is a registered trademark belonging to Valeant Pharmaceuticals International, Inc.SUSTIVA® is a registered trademark of Bristol-Myers Squibb Pharma Company.TAMIFLU® is a registered trademark belonging to Hoffmann-La Roche Inc.For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).     GILEAD SCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF INCOME(unaudited)(in thousands, except per share amounts)     2012   20112012   2011 Revenues: Product sales $ 2,357,978 $ 2,065,859 $ 6,887,560 $ 5,969,025 Royalty, contract and other revenues 68,619   55,801   226,672   215,982   Total revenues 2,426,597   2,121,660   7,114,232   6,185,007   Costs and expenses: Cost of goods sold 597,269 531,989 1,795,545 1,539,963 Research and development 465,831 290,066 1,320,286 826,915 Selling, general and administrative 319,583   295,927   1,095,209   895,764   Total costs and expenses 1,382,683   1,117,982   4,211,040   3,262,642   Income from operations 1,043,914 1,003,678 2,903,192 2,922,365 Interest expense (89,322 ) (43,097 ) (275,010 ) (130,420 ) Other income (expense), net (3,505 ) 14,406   (38,665 ) 40,216   Income before provision for income taxes 951,087 974,987 2,589,517 2,832,161 Provision for income taxes 280,052   237,449   774,877   704,861   Net income 671,035 737,538 1,814,640 2,127,300 Net loss attributable to noncontrolling interest 4,470   3,586   14,385   11,192   Net income attributable to Gilead $ 675,505   $ 741,124   $ 1,829,025   $ 2,138,492   Net income per share attributable to Gilead common stockholders - basic $ 0.89   $ 0.97   $ 2.42   $ 2.72   Net income per share attributable to Gilead common stockholders - diluted $ 0.85   $ 0.95   $ 2.33   $ 2.66   Shares used in per share calculation - basic 757,385   767,033   757,032   787,272   Shares used in per share calculation - diluted 792,304   781,312   783,824   802,762     GILEAD SCIENCES, INC.RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION(unaudited)(in thousands, except percentages and per share amounts)         2012   20112012   2011Cost of goods sold reconciliation: GAAP cost of goods sold $ 597,269 $ 531,989 $ 1,795,545 $ 1,539,963 Stock-based compensation expenses (1,864 ) (2,234 ) (6,084 ) (7,765 ) Acquisition related-amortization of purchased intangibles (15,837 ) (17,407 ) (47,509 ) (52,222 ) Non-GAAP cost of goods sold $ 579,568   $ 512,348   $ 1,741,952   $ 1,479,976     Product gross margin reconciliation: GAAP product gross margin 74.7 % 74.3 % 74.0 % 74.3 % Stock-based compensation expenses 0.1 % 0.1 % 0.1 % 0.1 % Acquisition related-amortization of purchased intangibles 0.7 % 0.8 % 0.7 % 0.9 % Non-GAAP product gross margin(1) 75.5 % 75.3 % 74.8 % 75.3 %   Research and development expenses reconciliation: GAAP research and development expenses $ 465,831 $ 290,066 $ 1,320,286 $ 826,915 Stock-based compensation expenses (23,236 ) (18,389 ) (162,214 ) (54,529 ) Restructuring expenses (232 ) (806 ) (7,322 ) (1,360 ) Acquisition related-transaction costs — — (345 ) (446 ) Acquisition related-contingent consideration remeasurement (58,810 ) (1,616 ) (64,116 ) (1,198 ) Non-GAAP research and development expenses $ 383,553   $ 269,255   $ 1,086,289   $ 769,382     Selling, general and administrative expenses reconciliation: GAAP selling, general and administrative expenses $ 319,583 $ 295,927 $ 1,095,209 $ 895,764 Stock-based compensation expenses (29,364 ) (25,897 ) (177,237 ) (83,821 ) Restructuring expenses (2,792 ) (4,388 ) (13,199 ) (6,054 ) Acquisition related-transaction costs (222 ) (535 ) (11,096 ) (1,278 ) Non-GAAP selling, general and administrative expenses $ 287,205   $ 265,107   $ 893,677   $ 804,611     Operating margin reconciliation: GAAP operating margin 43.0 % 47.3 % 40.8 % 47.2 % Stock-based compensation expenses 2.2 % 2.2 % 4.9 % 2.4 % Restructuring expenses 0.1 % 0.2 % 0.3 % 0.1 % Acquisition related-transaction costs 0.0 % 0.0 % 0.2 % 0.0 % Acquisition related-amortization of purchased intangibles 0.7 % 0.8 % 0.7 % 0.8 % Acquisition related-contingent consideration remeasurement 2.4 % 0.1 % 0.9 % 0.0 % Non-GAAP operating margin(1) 48.5 % 50.7 % 47.7 % 50.6 %   Interest expense reconciliation: GAAP interest expense $ (89,322 ) $ (43,097 ) $ (275,010 ) $ (130,420 ) Acquisition related-transaction costs —   —   7,333   —   Non-GAAP interest expense $ (89,322 ) $ (43,097 ) $ (267,677 ) $ (130,420 )   Net income attributable to Gilead reconciliation: GAAP net income attributable to Gilead, net of tax $ 675,505 $ 741,124 $ 1,829,025 $ 2,138,492 Stock-based compensation expenses 39,442 35,221 304,282 109,750 Restructuring expenses 2,165 3,908 14,937 5,569 Acquisition related-transaction costs 123 535 13,665 1,724 Acquisition related-amortization of purchased intangibles 11,462 13,172 34,581 39,225 Acquisition related-contingent consideration remeasurement 60,243   1,213   64,116   900   Non-GAAP net income attributable to Gilead, net of tax $ 788,940   $ 795,173   $ 2,260,606   $ 2,295,660     Diluted earnings per share reconciliation: GAAP diluted earnings per share $ 0.85 $ 0.95 $ 2.33 $ 2.66 Stock-based compensation expenses 0.05 0.05 0.39 0.14 Restructuring expenses 0.00 0.01 0.02 0.01 Acquisition related-transaction costs 0.00 0.00 0.02 0.00 Acquisition related-amortization of purchased intangibles 0.01 0.02 0.04 0.05 Acquisition related-contingent consideration remeasurement 0.08   0.00   0.08   0.00   Non-GAAP diluted earnings per share(1) $ 1.00   $ 1.02   $ 2.89   $ 2.87     Shares used in per share calculation (diluted) reconciliation: GAAP shares used in per share calculation (diluted) 792,304 781,312 783,824 802,762 Share impact of current stock-based compensation rules (1,310 ) (2,096 ) (1,427 ) (2,007 ) Non-GAAP shares used in per share calculation (diluted) 790,994   779,216   782,397   800,755     Non-GAAP adjustment summary: Cost of goods sold adjustments $ 17,701 $ 19,641 $ 53,593 $ 59,987 Research and development expenses adjustments 82,278 20,811 233,997 57,533 Selling, general and administrative expenses adjustments 32,378 30,820 201,532 91,153 Interest expense adjustments —   —   7,333   —   Total non-GAAP adjustments before tax 132,357 71,272 496,455 208,673 Income tax effect (18,922 ) (17,223 ) (64,874 ) (51,505 ) Total non-GAAP adjustments after tax $ 113,435   $ 54,049   $ 431,581   $ 157,168     Note: (1) Amounts may not sum due to rounding   GILEAD SCIENCES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)     September 30,December 31,20122011(unaudited)(Note 1) Cash, cash equivalents and marketable securities $ 2,651,088 $ 9,963,972 Accounts receivable, net 1,766,091 1,951,167 Inventories 1,617,369 1,389,983 Property, plant and equipment, net 856,184 774,406 Intangible assets, net 11,735,354 1,062,864 Goodwill 1,078,919 1,004,102 Other assets 1,258,824   1,156,640 Total assets $ 20,963,829   $ 17,303,134   Current liabilities $ 4,802,148 $ 2,514,790 Long-term liabilities 7,411,519 7,920,995 Stockholders' equity (Note 2) 8,750,162   6,867,349 Total liabilities and stockholders' equity $ 20,963,829   $ 17,303,134 Notes: (1) Derived from the audited consolidated financial statements as of December 31, 2011. (2) As of September 30, 2012, there were 757,933 shares of common stock issued and outstanding.   GILEAD SCIENCES, INC.PRODUCT SALES SUMMARY(unaudited)(in thousands)         2012   20112012   2011 Antiviral products: Atripla – U.S. $ 539,797 $ 501,576 $ 1,672,676 $ 1,474,580 Atripla – Europe 270,273 254,957 821,094 775,167 Atripla – Other International 55,308   38,166   163,227   111,456 865,378   794,699   2,656,997   2,361,203   Truvada – U.S. 414,452 357,660 1,180,791 1,011,837 Truvada – Europe 329,936 319,149 980,626 940,312 Truvada – Other International 59,802   67,918   186,969   176,990 804,190   744,727   2,348,386   2,129,139   Viread – U.S. 98,969 87,712 282,737 240,420 Viread – Europe 81,962 82,927 250,955 245,062 Viread – Other International 33,978   22,248   88,324   61,517 214,909   192,887   622,016   546,999   Complera / Eviplera – U.S. 82,099 19,044 195,742 19,044 Complera / Eviplera – Europe 14,306 — 24,771 — Complera / Eviplera – Other International 2,892   —   3,873   — 99,297   19,044   224,386   19,044   Stribild – U.S. 17,511   —   17,511   —   Hepsera – U.S. 12,615 14,170 33,596 42,809 Hepsera – Europe 11,999 18,223 41,384 60,293 Hepsera – Other International 2,705   3,238   7,827   9,281 27,319   35,631   82,807   112,383   Emtriva – U.S. 4,717 4,666 13,580 12,482 Emtriva – Europe 1,617 1,772 5,169 5,162 Emtriva – Other International 895   1,229   3,070   3,331 7,229   7,667   21,819   20,975   Total Antiviral products – U.S. 1,170,160 984,828 3,396,633 2,801,172 Total Antiviral products – Europe 710,093 677,028 2,123,999 2,025,996 Total Antiviral products – Other International 155,580   132,799   453,290   362,575 2,035,833   1,794,655   5,973,922   5,189,743   Letairis 105,054 78,954 293,976 214,765 Ranexa 95,066 81,983 273,822 236,353 AmBisome 87,448 82,241 255,865 249,372 Other products 34,577   28,026   89,975   78,792 322,145   271,204   913,638   779,282   Total product sales $ 2,357,978   $ 2,065,859   $ 6,887,560   $ 5,969,025 Gilead Sciences, Inc.InvestorsRobin Washington, 650-522-5688Patrick O'Brien, 650-522-1936orMediaAmy Flood, 650-522-5643